This bill expands the authority for healthcare providers in Washington, D.C., to follow immunization guidelines beyond just the CDC's Advisory Committee on Immunization Practices (ACIP). It amends two laws to allow the Director of the Department of Health to designate other competent medical or public health organizations (via public notice) whose recommended schedules providers must follow. This directly affects healthcare providers ordering/administering vaccines and the consent process for minors' vaccinations under the 2022 law. The change replaces specific CDC references with broader flexibility while maintaining that vaccines must align with official schedules. It is an emergency measure effective for 90 days.
This resolution (PR 26-0317) approves rules allowing licensed medical cannabis businesses in D.C. to fix products that fail testing for issues that can be corrected without patient harm - rather than destroying them. It directly affects businesses operating under D.C.'s Medical Cannabis Program by enabling remediation (e.g., removing contaminants) and repurposing usable products. The rules align D.C. with other states like Virginia and reduce waste by preventing unnecessary product destruction. The resolution seeks Council approval for these finalized rules, which were adopted by the Alcoholic Beverage and Cannabis Board and published in the District of Columbia Register.
This procedural resolution (PR 26-0106) approves Contract Modifications Nos. 8 and 9 for a pharmacy benefit management system under Contract No. CW94739 with Ramsell Corporation, authorizing payment for services provided from January 2025 through January 2026. It specifically exercises the remaining third option year of the contract, increasing the total value from $998,000 to $10,500,000. The resolution declares an emergency to expedite Council approval under DC Home Rule Act requirements, ensuring Ramsell Corporation can be paid for vital health services without disruption.
This bill requires health insurers in the District of Columbia to cover elective egg freezing (oocyte cryopreservation) as a fertility treatment starting January 1, 2027. It directly affects DC residents who may want to proactively freeze eggs to address age-related fertility decline later in life. Key provisions mandate coverage for at least three egg retrievals, unlimited embryo transfers from those eggs (following medical guidelines), and 10 years of storage, for both large group and individual/small group health plans. The law amends existing coverage requirements to include this proactive fertility care option.
This resolution approves two contract modifications for United Medical Center (UMC) to pay Aya Healthcare, Inc. for nursing staff. It authorizes $3.2 million for retroactive staffing costs (January 2024-January 2025) and $1.2 million for future staffing through March 2025, totaling over $1 million in a 12-month period. The hospital needs this payment authorization to maintain essential nursing services amid staffing shortages caused by national competition and UMC’s planned closure. Without Council approval, UMC cannot legally pay for these critical services.
This resolution approves updated regulations for Washington D.C.'s medical cannabis program, directly affecting patients, cannabis businesses, and the Alcoholic Beverage and Cannabis Board (ABCB). Key changes include modeling application, protest, and enforcement processes on existing alcohol licensing systems, and adjusting patient purchase limits to reflect different cannabis product types. The rules, voted on by the ABCB in November 2024, aim to create a more orderly and efficient medical cannabis market without requiring new legislative authority. Implementation will use existing budget resources, as confirmed by the Chief Financial Officer.
This bill prohibits insurance companies in Washington, D.C., from considering the use of HIV prevention medication (PrEP) when making decisions about disability, life, or long-term care insurance. It directly affects people using PrEP - such as daily pills (Truvada, Descovy) or the injection (Apretude) - who might otherwise face higher premiums, denied coverage, or limited benefits. The key provision amends existing anti-discrimination law to ban insurers from using PrEP use as a factor in underwriting, renewing, or pricing these policies. This aims to remove barriers to PrEP uptake and reduce stigma, supporting D.C.'s goal to lower new HIV diagnoses to under 130 annually by 2030.
This bill temporarily amends two District of Columbia laws to expand the immunization guidelines healthcare providers can follow. It replaces references to "CDC guidelines" with "CDC's Advisory Committee on Immunization Practices (ACIP) or a competent medical/public health organization designated by the DC Health Director." This change directly affects healthcare providers (like clinics and hospitals) and minor patients, allowing them to use approved guidelines from organizations beyond CDC, as designated by the Health Director. The amendment expires 225 days after enactment, making it a temporary adjustment to vaccination protocols.
This bill creates a new "craft preparation endorsement" for medical cannabis retailers in Washington, D.C., allowing them to prepare specific products on their licensed premises for sale to qualifying patients and caregivers. Retailers with this endorsement can make edibles (using cannabis oil or butter from licensed manufacturers), topical products like lotions, and prerolls, but must follow strict rules: products must be shelf-stable (no refrigeration needed), cannot include transdermal patches, and must avoid butane extraction. The endorsement limits preparation space to 20% of the retail area, restricts stored materials to 2 kilograms of flower and 1 liter of oil/tincture from licensed sources, and prohibits selling to other retailers or allowing detectable odors from preparation.
This bill clarifies that the District of Columbia's Department of Health Care Finance (DHCF) must cover and reimburse remote patient monitoring for specific health metrics during pregnancy and up to 12 months postpartum. It specifically requires coverage for remote monitoring of blood pressure and blood glucose levels, directly affecting pregnant individuals and new mothers in DC who manage conditions like gestational hypertension (8.5% prevalence) or gestational diabetes (5% prevalence). The amendment narrows the scope of the 2013 Telehealth Reimbursement Act to focus exclusively on these two health metrics, addressing prior budget concerns about broad digital health coverage. This change aims to improve maternal health outcomes by enabling early complication detection, as supported by studies showing 43% better postpartum blood pressure control with such monitoring.
